Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 14 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

29%

4 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (5)
P 1 (2)
P 2 (1)
P 3 (1)
P 4 (3)

Trial Status

Completed7
Withdrawn2
Recruiting2
Unknown2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07273656Phase 3Not Yet RecruitingPrimary

Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead

NCT05060237Phase 1Completed

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

NCT06206681Recruiting

Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors

NCT05942794Not ApplicableRecruiting

Identification of Oral Lesions Through an Autofluorescence System

NCT04336514Not ApplicableUnknown

A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures

NCT02851693Not ApplicableWithdrawn

Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection

NCT02813902Phase 1Withdrawn

A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors

NCT02737176Not ApplicableUnknown

Tobacco Cessation Intervention Study for Oral Diseases

NCT00121511Not ApplicableCompleted

The Effect of Efudex Treatment on Photoaged Skin

NCT00239135Phase 2CompletedPrimary

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00116649Phase 4CompletedPrimary

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00110682Phase 4CompletedPrimary

Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses

NCT00114023CompletedPrimary

1-Year Follow up to the 1473-IMIQ Study

NCT00115154Phase 4CompletedPrimary

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

Showing all 14 trials

Research Network

Activity Timeline